Subscribe
Pet Health & Wellness
10 min read

Jane Lauder | Founder, TAW Ventures

After nearly three decades at Estée Lauder Companies, Jane Lauder is applying prestige beauty’s standards of rigor, trust, and long-term brand equity to pet health through TAW Ventures. She shares how she evaluates founders, why pet longevity is still underestimated, and where she sees the biggest white space emerging over the next decade.

Written by
Roy Ben-Tzvi
Published on
November 11, 2026
Jane Lauder, Founder of TAW Ventures

After nearly three decades helping build one of the most trusted portfolios in consumer brand history, Jane Lauder is now applying those same standards of rigor, trust, and long-term brand equity to the pet industry.

Through TAW Ventures, she's backing founders working at the intersection of science, longevity, and the human–animal bond — areas she believes are still underestimated despite the surge of capital into pet.

In this conversation, Jane shares how prestige beauty principles translate into pet health, what separates durable brands from short-term trends, and where she sees the biggest white space emerging over the next decade.

‍

You spent nearly 30 years inside The Estée Lauder Companies. How did that experience prepare you for this new chapter in your professional career?

I grew up professionally at The Estée Lauder Companies, and those years shaped how I think as a leader. I learned how to build brands that become part of people's daily routines, which is incredibly personal. So much of that is about earning trust and creating an emotional connection. In prestige beauty, consumers are discerning and informed. They expect products to work, they expect transparency, and they expect proof behind every promise.

I've found that mindset translates directly to pet health and wellness. Today's pet parents are asking the same kinds of questions I saw emerge in beauty: What's in this? Does it work? Can I trust who is behind it? After nearly three decades where quality, efficacy, and consumer trust were non-negotiable, moving into pet felt less like a career pivot and more like an opportunity to apply those same principles to a category I'm deeply passionate about.

More on TAW Ventures from The Underbite

Subscribe to newsletter

Join our newsletter to stay up to date on features and releases.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

By clicking Sign Up you're confirming that you agree with our Terms and Conditions.

Pro
Keep Reading

Other Interviews

More conversations with founders, operators, and investors building the future of pet care.

Learn more
Deven Vespi | Advisor, DRV Advisory
Pet Health & Wellness
13 min read

Deven Vespi | Advisor, DRV Advisory

Clinically proven has no shared definition in pet, yet it now shapes deals as much as labels. Deven Vespi learned the trade in FDA-regulated animal health, and she explains how to check a study before you trust it or build a deal on it. She covers sample sizes, dosing gaps, why brands get blindsided by their own research, and how long published data stays an edge.

Learn more
Learn more
Meet the Founders: 3 Startups Shaping the Future of Pet Health
Pet Health & Wellness
10 min read

Meet the Founders: 3 Startups Shaping the Future of Pet Health

Pawsible Ventures took seven of more than 130 applicants into its second cohort. Three of them work very different corners of pet health. Nicole Shlomof and Gila Leibovitch of Pawp Water sell functional water to owners who already fill the bowl, Andria Beal of EpiPaws turned dolphin epigenetics research into biological-age tests for dogs and cats, and Elliot Greenwood of ChckVet sells software to vet practices that resist new tech.

Learn more
Learn more
Elizabeth Iorns | Co-Founder & CEO, Familiar Therapeutics
Pet Health & Wellness
17 min read

Elizabeth Iorns | Co-Founder & CEO, Familiar Therapeutics

Elizabeth Iorns lost her French Bulldog to a brain tumor that a published canine study suggested could be treated, but no company had taken the drug forward for dogs. Now she and Science Exchange co-founder Dan Knox license the companion animal rights to human drugs at Familiar Therapeutics: 13 programs and $5 million raised in five months, plus a pitch to pharma that pet trials validate targets faster than phase two.

Learn more
View all interviews